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ABSTRACT 
Background:  
It has been shown that elderly patients have decreased anesthetic requirements due to 
age-related changes in pharmacokinetics, pharmacodynamics and drug sensitivity.  
Previous work has also shown that anesthetic dosing is often not being rigorously 
corrected for age. 
 
Purpose:  
To determine whether the dosing of intravenous (IV) induction anesthetics in patients 
undergoing gastrointestinal (GI) surgeries are corrected appropriately for age. 
 
Methods:  
We retrospectively reviewed the intraoperative electronic anesthetic records of 1868 adult 
patients (aged ≥ 18 yrs) receiving general anesthesia for GI surgeries from February 2013 
– January 2014. Patients undergoing multiple procedures, those requiring temporary 
abdominal closure or rapid sequence induction were excluded from this study. Change in 
mean arterial pressure (MAP) was calculated as the difference between pre- and post-
induction MAP. Post-induction MAP was measured within the first 10 minutes of 
induction. Statistical analysis was done using T-test and one-way ANOVA. 
 
Results:  
There was a significant decrease in dosing of fentanyl, propofol and midazolam with 
increasing age (p<0.05).  There was a significantly larger drop in MAP following 
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induction of anesthesia in older patients (ages > 70 yrs) despite the decrease in weight-
based dosing (p<0.01). Patients aged 70 yrs and under had a mean decrease in MAP of 
17.16 ±	 19.51	 mm Hg, whereas patients over the age of 70 had a mean decrease in MAP 
of 23.23 ±	 25.09 mm Hg.  We noted a significant decrease in dosing of fentanyl and 
propofol with increasing ASA class (p-values <0.01).  No significant difference in dosing 
of midazolam was seen based on ASA class (p=0.47). For ASA III and IV patients 
(n=792), there was no significant change in dosing of fentanyl based on age.   
 
Conclusion:  
The results of this study show that there is a significant age-related decrease in the 
induction dosing of fentanyl, propofol and midazolam.  This change remains significant 
for propofol after correcting for ASA class.  However, the age-corrected doses for these 
induction anesthetics tend to be either higher, or at the upper limit, of recommended 
dosing for the elderly patients, which may explain a larger drop in MAP following 
induction in elderly vs. younger patients. 
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LITERATURE REVIEW 
Epidemiology 
The elderly population (those who are 65 years of age and older) is currently the 
fastest growing portion of the population in the United States.  Between 2000 and 2010, 
the population of those 65 years and over has increased at a faster rate (15.1%) than the 
total US population (9.7%).  According to the 2010 US Census, 40 million people (13%) 
of the total US population of 309 million people are 65 years and over [1].  In 
Connecticut, there were over half a million individuals 65 years and older in 2010 and 
they comprised 14.2% of the total state population [2].  The older population in the US, is 
projected to double from 36 million in 2003 to 72 million in 2030 and 86.7 million by 
2050.  The 85 and older group composes a small, but rapidly growing proportion of this 
older population [3].  This is in part due to increased life expectancies as a result of 
improving medical care and nutrition.  The average life expectancy in the United States 
has risen from 47.3 years in 1900 to 76.9 years in 2000.  A second contributing factor is 
that many of those in the baby boomer generation began to turn 65yrs in 2011 [3].   
This rapidly growing older population has also increased the surgical and 
anesthesia workload for US hospitals.  It is estimated that surgical interventions will be 
required by more than half of the population older than 65 years, at least once during the 
remainder of their lives [4].  A study done by Elixhauser et al in 2007 found that there 
were 15 million operating room (OR) procedures performed in US hospitals that year.  
They also found that elderly patients underwent these procedures 2 to 3 times more 
frequently than younger patients [5].    
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Pathophysiologic changes in the elderly 
As the body ages, there are many pathophysiological changes that take place, and 
many of these changes can affect the pharmacokinetics and pharmacodynamics of 
commonly used anesthetic drugs.  Overall pathophysiological changes result in a 
decrease in functional reserve in almost all organ systems. 
 Cardiovascular aging predominantly manifests in increased tissue stiffness and 
fibrosis, decreased response to beta-receptor stimulation, increased sympathetic nervous 
system activity and the loss of ischemic preconditioning [6].  The increased tissue 
stiffness causes the arteries, veins and myocardium to become less compliant, which in 
turn causes systolic hypertension and ventricular hypertrophy.  In response to these 
changes, the ventricles hypertrophy and become more dependent on adequate end-
diastolic atrial filling to maintain cardiac output.  A diminished response to beta-receptor 
stimulation leads to reduced heart rate and contractile response to stimuli such as 
hypotension, exercise, or exogenous catecholamine administration.  This reduction in the 
heart’s ability to increase contractility increases the dependence on the Frank-Starling 
mechanism to maintain cardiac output, leading to an increase in pre-load and modestly 
decreased heart rate [6, 7].  It was previously thought that cardiac output decreased in an 
almost linear manner after the third decade of life [8], however newer longitudinal studies 
fail to show significant age-associated decline in cardiac output at rest or during exercise 
in healthy adults between ages 25 and 79 [9].  
 The most important feature of aging from a respiratory standpoint is the gradual 
reduction in elastic recoil of the lung tissue due to changes in the arrangement and 
strength of the elastic fiber network [10].  There is also a gradual decrease in compliance 
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of the chest wall as the body ages.  While the total lung capacity remains the same 
throughout life, the vital capacity diminishes with age [8, 11]. After the age of 20, vital 
capacity decreases 20 to 30 ml per year.  This is due to the fact that while total lung 
capacity remains unchanged, there is an increase in the residual volume of 5 to 10% per 
decade[11].  In addition to these changes in respiratory mechanics, there is a significant 
decrease in the efficacy of arterial oxygenation in the elderly, which is reflected by an 
almost linear loss of oxygen partial pressure in the arterial blood after the age of 20 [12], 
which in part is due to reduced surface area for gas exchange as the integrity of the lung 
parenchyma is progressively lost with age [13].  The decreased arterial oxygen tension, 
reduced gas exchange, and increased closing capacity all contribute to increased V/Q 
mismatch in the elderly [10].  The net effect of these changes results in increased work of 
breathing and decreased sensitivity to hypoxic and hypercapnic stimuli in the elderly 
[10].  Structurally, there is a loss of recoil forces that tend to hold small airways open, 
and this results in a greater number of airways closing at equivalent lung volumes when 
comparing older patients to their younger counterparts [14].  This puts the older patients 
at a higher risk for atelectasis and perioperative pulmonary complications.  
 As the nervous system ages, there is a progressive loss of neuronal tissue, which 
is reflected in a reduction in the average weight of the brain with age [15]. The volume of 
the brain declines with age at a rate of about 5% per decade after the age of 40 with the 
actual rate of decline possibly increasing with age, particularly over the age of 70 [16].  
Grey matter decreases faster than white matter from 20 to 50 years of age, however after 
the age of 50 there is more white matter lost than gray matter with an eventual gray/white 
matter ratio of 1.55 by the age of 100 [15].  In addition to decrease in nervous tissue 
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mass, there is a loss of neuronal density, concentration of neurotransmitters, and 
norepinephrine and dopamine receptors [17].  The brain’s choline acetyltransferase levels 
and muscarinic binding decrease with increasing age, as does cholingeric innervation in 
the caudate nucleus.  There are also age-associated declines in levels of striatal dopamine 
uptake sites, dopamine transporters and dopamine levels.  Cerebral cortical α2 and β2 (but 
not total β) adrenoreceptors  also show an age-associated decrease.  Finally, GABA-ergic 
innervation of the cortex also appears to decline with age [18].  This is particularly 
important for centrally-acting agents such as propofol and midazolam, which are known 
to act on GABA receptors.  The blood-brain barrier decreases in microvascular density 
and capillary lumen size, both of which increase its permeability [19]. 
 The kidneys are characterized by a progressive loss of renal mass with aging due 
to glomerulosclerosis, thickening of the vascular intima, fibrosis of the stoma and chronic 
infiltration by inflammatory cells.  This results in a decline in renal plasma flow and 
glomerular filtration rate [8, 20].  There is approximately a 7.5 to 8 ml/min decline in 
GFR per decade[21].  The Baltimore longitudinal study of aging used both cross-
sectional and longitudinal data over 10 years, and it reported a decline in creatinine 
clearance with increasing age.  In addition, the longitudinal studies showed that the rate 
of decline of renal function also increases with age [22].  Newer longitudinal studies 
using the same population, however reported that 1/3 of all subjects had no decrease in 
renal function, with a small group with actual increase in clearance rate [23].  Overall, it 
appears that the majority of elderly patients do exhibit declines in creatinine clearance, 
but great variability does exist from person to person. 
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 From a metabolic standpoint, there is a decrease in liver volume as individuals 
approach the end of the 9th decade, however recent studies have shown that there is no 
significant age-dependent difference in the activity of phase I, phase II or cytochrome 
p450 metabolism [24-26].  There is a 40% reduction in liver blood flow that occurs as 
individuals approach the end of the 9th decade [27].   
 Overall body composition also changes with age.  There are relative decreases in 
total body water and lean body mass, while there is a relative increase in body fat [28].  
Decreases in height in older individuals of either gender are almost linear with age 
whereas decreases in weight occur at different rates in men and women [14, 29]. 
 
Pharmacodynamic and pharmacokinetic changes in the elderly 
 Many of the factors related to pharmacokinetics and pharmacodynamics (PK/PD) 
are altered with aging and have been described above.  The net result of these 
pathophysiologic changes as related to the pharmacology of anesthetic drugs is complex.   
From a pharmacokinetic standpoint, there are many factors that contribute to the 
absorption, distribution, metabolism and excretion of anesthetic drugs, and many of these 
variables change as people age.  Drug absorption is for the most part a passive process 
and the extent of absorption depends on the absorptive capacity of the small bowel, and 
this shows little change with increasing age [28].  However, the distribution of drugs is 
heavily dependent on body composition, which as was mentioned earlier, goes through 
significant change with age.  Relative changes in body fat and lean body mass associated 
with aging can affect the volume of distribution (Vd) for many drugs.  As the percentage 
of fat content increases, fat-soluble drugs will have a relatively increased Vd, and water-
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soluble drugs will have a relatively decreased Vd [14, 28].  Vd is also a determinant of 
plasma concentration in acute dosing, and therefore is a major determinant in IV 
induction dosing. 
Pharmacokinetics is often described with the three-compartment model (Figure 
1).  This model consists of a central compartment (V1), a rapidly equilibrating 
compartment (V2), and a slowly equilibrating compartment (V3) [30].  The central 
compartment (V1) consists of the central plasma pool.  The rapidly equilibrating 
compartment (V2) consists of the hepatoportal system and to some extent the viscera.  
The slowly equilibrating compartment (V3) represents tissue such as muscle and fat, 
where there is decreased perfusion in comparison to V2 [31].  These compartments help 
to explain the three phases of drug distribution.  When a drug is given IV, it goes into V1, 
and it is followed by a rapid distribution phase where there is rapid movement of the drug 
from the plasma into the rapidly equilibrating tissues.  Often, there is a second slow 
distribution phase where there is movement of the drug into more slowly equilibrating 
tissues and return of the drug to the plasma from the rapidly equilibrating tissues.  Finally 
the terminal phase involves drug return from both V2 and V3 back into V1 and is 
permanently removed by metabolism or excretion [30].  Therefore, increases in the 
relative fat content with increasing age leads to alterations in duration of drug effect in 
the elderly due to an increase in V3 [14, 28].  A relative decrease in total body water 
leads to a decrease in V1, which results in higher peak drug concentrations following 
boluses or rapid infusions [14, 32].   
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Figure 1. Schematic for the three-compartment model of drug pharmacokinetics [30] 
 
 Plasma protein drug binding varies for each individual drug and there are small 
but significant changes in serum albumin concentrations with aging.  This results in 
increased free drug concentrations in elderly patients [33].  These changes are often not 
clinically relevant in healthy older patients, however elderly patients often have 
significant decline in albumin levels with severe illness or malnutrition, which could 
significantly increase the free plasma concentration of certain drugs [28].  Malnutrition in 
the elderly is common and has also been shown to be an independent predictor of 
institutionalization rate [34] and mortality in elderly patients and can be considered a 
marker of frailty in the elderly.  Therefore it is expected to reflect an individual’s 
susceptibility to acute health problems [35]. 
 The rate of drug metabolism and a certain degree of drug elimination are mainly 
functions of the liver and these processes have been shown to decrease with advancing 
age [36, 37].  However, recent studies have not shown a significant decrease in liver 
function or histology [24-26], which suggests that the decreased rate of drug metabolism 
PART III: Anesthetic Pharmacology596
to the concentration of drug distributed via circulation 
to the liver. As was shown earlier, this means that meta-
boli  clearance is usually co stan  and independent of 
dose.
Physiologic Pharmacokinetic Models
It is possible to analyze volumes and clearances for each 
organ in the ody and construct models of pharmaco-
kinetics by assembling the organ models into physio-
logically and anatomically accurate models of the entire 
animal.4 Models that work with individual tissues are 
mathematically cumbersome and do not offer a better 
prediction of plasma drug concentration th n models 
that lump the tissues into a few compartments. If the goal 
is to determine how to give drugs to obtain therapeutic 
plasma drug concentrations, all that is needed is to math-
ematically relate dose to plasma concentration. For this 
purpose, conventional compartmental models are usually 
adequate.
Compartmental Pharmacokinetic Models
Compartmental models are built on the same basic con-
cepts as physiologic models, but with gross simplifica-
tions. The one-compartment model seen in Figure 24-12 
contains a single volume and a single clearance, as though 
humans were built like tanks. For anesthetic drugs, 
human bodies resemble several tanks connected by pipes. 
These are usually modeled by two- or three- compartment 
models, also shown in Figure 24-12. The volume to the 
right in the two-compartment model—and in the center 
of the three-compartment model—is the central volume. 
The other volumes are peripheral volumes. The sum of 
all volumes is the volume of distribution at steady state, 
Vdss. Clearance in which the central compartment is left 
for the outside is the central, or metabolic, clearance. 
Clearances between the central compartment and the 
peripheral compartments are the intercompartmental 
clearances.
Multicompartment Models
Plasma concentrations over time after an intravenous 
bolus resemble the curve in Figure 24-13. This curve has 
the characteristics common to most drugs when given by 
intravenous bolus. First, the concentrations continuously 
decrease over time. Second, the rate of decline is initially 
steep but continuously becomes less steep, until we get to 
a portion that is log-linear.
For many drugs, three distinct phases can be distin-
guished, as illustrated in Figure 24-13. A rapid-distribution 
phase (blue line) begins immediately after injection of the 
bolus. Very rapid movement of the drug from plasma to 
the rapidly equilibrating tissues characterizes this phase. 
Frequently, there is a second, slow-distribution, phase 
(red line), which is characterized by movement of drug 
into more slowly equilibrating tissues and return of drug 
to plasma from the most rapidly equilibrating tissues. The 
terminal phase (green line) is a straight line when plot-
ted on a semilogarithmic graph. The terminal phase is 
often called the elimination phase because the primary 
mechanism for decreasing drug concentration during the 
terminal phase is elimination of drug from the body. The 
distinguishing characteristic of the terminal elimination 
phase is that the plasma concentration is lower than tis-
sue concentrations and the relative proportion of drug in 
plasma and peripheral volumes of distribution remains 
constant. During this terminal phase, drug returns from 
the rapid- and slow-distribution volumes to plasma and 
is permanently removed from plasma by metabolism or 
excretion.
The presence of three distinct phases after bolus injec-
tion is a defining characteristic of a mammillary model 
V1
Central
compartment
V
Volume of
distribution
V2
Peripheral
compartment
Drug administration
One-compartment
model
Two-compartment
model
Drug administrationDrug administration
k12
k10k
II
k21
Three-compartment
model
V3
Slowly equilibrating
compartment
V2
Rapidly equilibrating
compartment
k12 k13
k21 k31
k10
I
V1
Central
compartment
Figure 24-12. One-, two-, and three-compartment mammillary 
models.
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n
Figure 24-13. Hydraulic model of fentanyl pharmacokinetics. Drug 
is administered into the central tank, from which it can distribute into 
two peripheral tanks, or it may be eliminated. The volume of the tanks 
is proportional to the volumes of distribution. The cross-sectional area 
of the pipes is proportional to clearance.5
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in the elderly is not necessarily due to changes in liver function.  A novel hypothesis by 
Le Couteur and Mclean suggests that there is hepatic sinusoid pseudocapillarization 
associated with aging that results in reduced diffusion and decreased drug metabolism 
[38].  Decreased blood flow to the liver may also contribute to the reduced rate of drug 
metabolism in the elderly [27].  Renal clearance of drugs is general reduced in the elderly 
population [28] due to both physiologic changes to the kidneys and reduced renal blood 
flow.  Therefore, the dose requirements of drugs excreted mainly by the kidney should be 
reduced in those patients with reduced renal function [28]. 
 Pharmacodynamic differences related to aging can be due to either differences in 
baseline performance or differences in sensitivity to the drug [39].  Mechanisms thought 
to contribute to these differences include altered neurotransmitters and/or receptors, 
hormonal changes, and impaired glucose metabolism or decreased availability of glucose 
and oxygen in the cerebral vasculature [16].  Drugs may also penetrate the CNS more 
easily with increasing age.  For example, P-glycoprotein is an efflux pump that actively 
transports some drugs out of the brain and the functional activity of this pump is reduced 
with aging.  This could potentially lead to increased drug exposure to the brain for older 
patients at given serum concentrations, leading to increased sensitivity to drugs that act 
on the central nervous system (CNS) [39].  Specific changes to PK/PD with age will vary 
for each drug based on the unique characteristics of each drug that affect its distribution, 
metabolism and elimination. 
 Overall, these changes results in higher peak drug concentrations, increased drug 
sensitivity, and decreased drug clearance in the elderly. This necessitates reductions in 
dosing for inhalational and IV anesthetic drugs. 
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IV induction medications and associated changes in PK/PD in the elderly 
 Commonly used IV induction medications include propofol, midazolam and 
fentanyl.  All three drugs have increased potency in the elderly [14].  These are a result of 
both pharmacokinetic and pharmacodynamics changes in the elderly that lead to 
decreased drug dosing requirements in the elderly.  The anesthetic potency of each IV 
drug can be quantified by its Cp50 value, which is defined as the plasma concentration 
required to prevent movement response in 50% of patients to surgical stimuli [40]. 
 Propofol is currently the most widely used IV hypnotic that acts on both GABA 
and NMDA receptors.  The brain becomes more sensitive to the effects of propofol with 
age, and Cp50 for propofol decreases with increasing age [41], with approximately a 30% 
reduction in a 90 year old patient versus a 30 year old [42].  This is because age 
influences the inter-compartmental drug distribution of propofol [42] and results in a 
reduction in systemic clearance, reduction in the size of the rapidly equilibrating 
compartment (V2) and reduction in inter-compartmental clearance to V2 [14], which 
would lead to higher plasma concentrations in older patients.  Therefore, for a given 
propofol infusion rate, the plasma concentration in a 75 year old will rise 20-30% higher 
than in a younger patient.  However, if given plasma concentrations are maintained with 
infusions of propofol, the plasma concentrations will fall faster in the 75 year old versus a 
25 year old when the infusion is turned off [42].  Although the plasma concentrations fall 
more quickly in older patients once drug administration is complete, it often take longer 
to return to consciousness due to the increased sensitivity to propofol in the elderly [43]. 
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In clinical practice, midazolam is often used immediately before induction of 
anesthesia to decrease anxiety and induce amnesia[44].  While overall pharmacokinetics 
do not change with age for midazolam, it does appear that the elderly are more sensitive 
to it [45, 46].  The Cp50 for midazolam decreases significantly between the ages of 40 
and 80 years old, with the Cp50 for 80 year olds being less than 25% of that for 40 year 
olds [47].  In addition, there is a reduction in the clearance of midazolam by 
approximately 30% in 80 year olds versus 20 year olds [48].  Overall this results in a 
significant decrease in the dosing requirements for the elderly.  Bell et al., noted a strong 
relationship between the dose of midazolam used and the subject’s age in a cohort of 
patients undergoing upper GI endoscopy.  They found that 7.2% of patients over the age 
of 70 required more than 5 mg for adequate sedation, while 83% of patients less than 70 
years old required more than 5 mg.  This correlated to a 75% decrease in dose 
requirement from age 20 to age 90 [49].   
Elderly patients also have an increased sensitivity to opioid analgesics such as 
fentanyl. As determined by EEG, there is approximately 50% depression in EEG in 85 
year olds compared to 20 year olds [50].  Overall pharmacokinetics of fentanyl, however 
do not appear to change with age [51, 52], and so this would translate clinically to a 
reduction of doses by one-half to achieve the same effect in older patients.  Similar 
reductions (50% decrease in EEG in 84 year olds compared to 20 year olds) were found 
in shorter-acting opioids such as remifentanil [53]. 
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Current IV induction anesthetic dosing recommendations in the elderly 
 Based on the pharmacokinetic and pharmacodynamics changes as discussed 
above, the current dosing recommendations for elderly patients require reductions from 
standard adult dosing.  Standard induction dosing for propofol in adults is 2-2.5mg/kg, 
however a dose of 1 mg/kg with premedication and 1.75 mg/kg without premedication is 
recommended for induction of patients older than 60 years [44, 54].  Induction dosing for 
midazolam can be up to 0.3 mg/kg in young healthy adults, however a reduction of at 
least 50% is recommended for patients over the age of 60 [44] .  Fentanyl is commonly 
given in combination with midazolam and propofol during induction at doses starting at 2 
mcg/kg.  However given that elderly patients are twice as sensitive to opioids, it is 
recommended that dosing for older patients to start at 1 mcg/kg although there is no 
consensus on the starting age at which the decreased dosing should be given [55].   
 Although recommendations exist for IV induction dosing for the elderly, it is not 
well known if elderly patients are receiving the correct dosing for their age, and whether 
the current recommendations are sufficient for our growing geriatric population.  In 
addition, we currently lacking in PK/PD data and recommendations for the very elderly 
patient population (>80 yrs).   
 
Impact of Severity of Illness on Drug Dosing and Clinical Outcomes 
 Since its formulation in 1941, the American Society of Anesthesiologists’ (ASA) 
physical status classification system was intended to provide a common language to 
describe patients severity of illness before surgery [56].  ASA I corresponds to a normal 
healthy patient and ASA IV corresponds to a patient with severe systemic disease that is 
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a constant threat to life.  Further definitions of the ASA classification system are detailed 
in Table A. This classification system has been shown to predict morbidity and mortality 
in surgical patients [57].  Studies have shown a strong correlation between increasing 
ASA class and decreasing requirements for induction dosing of propofol [58], which 
suggests that patients with increased severity of illness require less propofol to induce 
adequate anesthesia than those without significant disease.   
 In addition to decreased anesthetic requirements, higher ASA classification (class 
III/IV) is independently associated with increased 1-year mortality following non-cardiac 
surgery [59].   Patients with higher ASA classifications have also been shown to have 
significantly longer hospitalizations for operative fixation of ankle procedures – a 1 point 
increase in ASA was associated with a 3.42 day increase in average length of stay [60].  
The prevalence of intraoperative hypotension is also greater in patients who are ASA 
III/IV (12.6%) versus ASA I/II (7.7%) [61]. 
 Although the ASA classification system is easily applied and communicated, the 
system lacks specificity, which leads to inconsistent ratings between anesthesiologists 
and imprecise clinical interpretation [57].  A meta-analysis of 77 studies looking at 
correlations between ASA classification and post-operative outcomes showed a pooled 
sensitivity of 0.74 and a pooled specificity of 0.66.  This specificity falls to 0.53 in the 
studies associated with high-risk surgical procedures [57]. 
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ASA PS Definition 
I A normal healthy patient 
II A patient with mild systemic disease 
III A patient with severe systemic disease 
IV A patient with severe systemic disease that is a constant 
threat to life 
V A moribund patient who is not expected to survive 
without the operation 
VI A declared brain-dead patient whose organs are being 
removed for donor purposes 
 
Table A. Definitions of the American Society of Anesthesiologists’ physical status 
classification levels 
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STATEMENT OF PURPOSE 
The purpose of this study is to evaluate whether IV induction anesthetics are being 
appropriately corrected for age and ASA class.  
 
METHODS 
Study Design 
A retrospective review was conducted for the intraoperative electronic anesthetic 
records of 1868 adult patients (aged 18 years and older) who had received general 
anesthesia for GI surgeries at Yale-New Haven Hospital.  Only patients who underwent 
IV induction were considered in this study.  GI surgery was defined as any procedure 
involving the GI tract or gallbladder.  Both laparoscopic and open abdominal procedures 
were included in the study.  Endoscopic procedures were not included in the current 
study.    
 
Patient Selection 
2471 adult patients scheduled to undergo GI procedures were identified from 
February 2013 to January 2014.   Patient exclusion criteria are summarized in Figure 2.  
Any patients who did not undergo traditional IV induction for anesthesia were excluded.  
This included patients who underwent RSI, MAC, inhalational anesthetic induction, 
epidural anesthesia, or were already intubated on arrival to the OR.  Patients who had 
multiple procedures or required temporary abdominal wall closure were also excluded.  
The final exclusion criteria involved any patients who were missing data points, such as 
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height, weight, pre-induction blood pressure, or post-induction blood pressure.  602 
patients were excluded and the final cohort size was 1869 patients.  
 
 
Figure 2. Exclusion flow chart for patient cohort. 
 
Data Collection 
Data were extracted from preoperative and intraoperative anesthesia electronic 
records.  Basic patient information included age, gender, height and weight.  Body 
surface area was calculated using the Mosteller equation: BSA (m2) = (height (cm) x 
weight(kg) / 3600 )½ .  Ideal body weight was also calculated based on height and gender.  
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For males, IBW = 50 kg + 2.3 kg for each inch over 5 feet.  For females, IBW = 45.5 kg 
+ 2.3 kg for each inch over 5 feet. 
The date of surgery, attending surgeon, procedure and ASA class were recorded.  
Two automated systolic and diastolic blood pressure readings were extracted from the 
electronic intraoperative anesthesia record for each patient – once prior to any 
administration of IV medication and once within 10 minutes of induction.  Induction was 
defined as the administration of IV propofol.  Mean arterial pressures were calculated 
using the recorded systolic and diastolic pressures.  The doses of propofol, fentanyl and 
midazolam were extracted from the records and the weight-based dosing was calculated.  
The presence or absence of post-induction hypotension (defined as post-induction mean 
arterial pressure of <70 mm Hg or reduction in MAP by 40%) was noted. 
 
Data Analysis 
Statistical analysis was done using T-test and one-way ANOVA, with p < 0.05 
considered significant.  Age-based analysis was done with the following age groups: 18 
to 30, 31 to 40, 41 to 50, 51 to 60, 61 to 70, 71 to 80, and >80 years old.  Changes in the 
average weight-based dosing of midazolam, fentanyl and propofol with increasing age 
were analyzed using one-way ANOVA.  A subsequent change in the average change in 
MAP from pre-induction to post-induction was also analyzed using one-way ANOVA.  
Analysis based on ASA class was also performed using one-way ANOVA. 
Comparisons between the average weight-based dosing for elderly patients 
(defined as >70 years old in this study) versus younger adult patients (18-70 yrs) were 
made using the student’s T-test.  Patients were further stratified by ASA class, and 
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patients were grouped into ASA I/II vs. ASA III/IV (Figure 3).  This was done to control 
for potential changes in dosing based on ASA class.  Further analysis was done using the 
Student’s T-test within these stratified groups. 
 
      
             Figure 3. Stratification scheme for both ASA class and age 
 
Distribution of Work 
Contact with the Human Investigations Committee of the Yale School of 
Medicine regarding initial and ongoing study approval was maintained by Shamsuddin 
Akhtar, MD, of the Department of Anesthesiology at the Yale School of Medicine.  The 
list of potential subjects was compiled by Jia Liu (YSM 2015).  Data were collected by 
Jia Liu.  Data analysis was performed by Jia Liu and Shamsuddin Akhtar, MD with 
assistance from Joseph Heng (YSM 2015).  
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RESULTS 
Patient Characteristics 
Of the 1869 patients in the final study cohort, 241 were over the age of 70 (age 
range 18-93).  55.9% of the patients were female and 44.1% were male.  1076 patients 
were classified as ASA I/II and 792 patients were classified as ASA III/IV (Figure 4).  
Average height for all patients was 1.68m, average weight was 86.64 kg and average 
calculated BSA was 2.00 m2.   Procedures included in this cohort were performed by 44 
different surgeons, over the course of one year.  The types of surgeries undergone by 
these patients are shown in Table B. 
Patients were then stratified by age, and patient characteristics for each age group 
are detailed in Table C.  There were no significant changes in average height with 
increasing age.  There was a trend of decreasing weight with increasing age starting at 
age 50.  A similar trend in body surface area was also noted starting at age 50.  Of note, 
for patients over the age of 70, only 58 patients were classified as ASA I/II versus 183 
patients who were classified as ASA III/IV.   
 
          
                                Figure 4. Age and ASA distribution of patients.  
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Type of GI Surgery Total Number 
Upper GI Surgery  363 
Lower GI Surgery 278 
Anal/Perianal Surgery 54 
Appendectomy 198 
Cholecystectomy 436 
Hernia Repair 478 
Exploratory Laparotomy/Lysis of Adhesions 52 
Other 10 
Total 1869 
   Table B. Distribution of surgery type for the study cohort 
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Age 
Range 
(in 
years) 
Total Female 
(%) 
ASA 
1&2 
only 
ASA 
3&4 
only 
Ratio of 
ASA 
1&2 and 
3&4 
Height 
(m) 
Weight 
(kg) 
BSA 
(m2) 
18-30 290 55.5 237 53 4.47 1.69 83.33 1.95 
31-40 253 67.6 183 70 2.61 1.68 91.92 2.05 
41-50 362 57.2 233 129 1.81 1.68 93.33 2.07 
51-60 399 49.4 223 176 1.27 1.70 89.26 2.04 
61-70 324 51.2 142 181 0.78 1.69 82.44 1.95 
71-80 179 54.7 49 130 0.38 1.67 79.34 1.91 
>80 yr 62 70.9 9 53 0.17 1.65 67.59 1.74 
Total 1869 55.9 1076 792 1.36 1.68 86.64 2.00 
 
Table C. Patient characteristics various age groups – height, weight and BSA are given 
as averages.  
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Age-Related Dosing 
There were significant decreases in dosing of fentanyl, propofol and midazolam 
with increasing age.  Average dose of fentanyl for the 18-30 year old age group was 1.41 
± 0.81 mcg/kg and >80 year old age group was 1.21 ± 0.80 mcg/kg.  Average dose of 
propofol for the 18-30 year old age group was 2.48 ± 0.83 mg/kg and >80 year old age 
group was 1.63 ± 0.59 mg/kg.  Average dose of midazolam for the 18-30 year old age 
group was 0.026 ± 0.16 mg/kg and >80 year old age group was 0.0017 ± 0.0053 mg/kg 
with the majority of patients receiving no midazolam during induction. (Figure 5).  
 
 
Figure 5.	  Average weight-based doses of different induction anesthetics and post-
induction changes in mean arterial pressure are represented for different age groups. 
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Standard error bars are included. Translucent shaded bars reflect recommended dosing 
ranges for the elderly. P-values were calculated using one-way ANOVA, with p<0.05 
considered significant. 
 
Pharmacodynamic effect 
There was a significantly larger drop in MAP following induction in older patients (>70 
years old) despite the decrease in weight-based dosing (Figure 5).  Patients aged 70 and 
under had an average decrease in MAP of 17.16 ±	 19.51 mm Hg (median 23.33 mm Hg) 
following IV induction, whereas patients over the age of 70 years had an average 
decrease in MAP of 23.23 ±	 25.09 mm Hg (median 17.33 mm Hg) following IV 
induction. There was also a trend in the average MAP following induction, with larger 
decreases with increasing age from age 40 and older.  Over 30% of patients over the age 
of 60 years experienced post-induction hypotension, and there was a similar percentage 
of patients aged 18 to 30 years old who also experienced post-induction hypotension 
(Table D).  
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Age Range 
(in years) 
Number of Patients with 
Post-Induction Hypotension 
Percentage of Patients with 
Post-Induction Hypotension 
(%) 
18-30 95/290 32.7 
31-40 66/253 26.1 
41-50 78/362 21.5 
51-60 83/399 20.1 
61-70 104/324 32.1 
71-80 65/179 36.3 
>80 23/62 37.1 
Total 514/1869 27.5 
Table D. Patients within each age group found to have post-induction hypotension 
 
Dosing Related to ASA Class 
 We noted a significant decrease in dosing of fentanyl and propofol with increasing 
ASA class (p-values < 0.01).  Fentanyl dosing decreased from an average of 1.39 ± 0.71 
mcg/kg for ASA-I to an average of 1.04 ± 0.94 mcg/kg for ASA-IV.  Propofol dosing 
decreased from an average of 2.63 ± 0.79 mg/kg for ASA-I to 1.57 ± 0.59 mg/kg for 
ASA-IV.  There was no significant difference in dosing of midazolam based on ASA 
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class (p=0.47) with an average dosing of 0.019 ± 0.013 mg/kg in ASA 1 and 0.0047 ± 
0.0097 mg/kg in ASA 4 patients. Figure 6 
 
 
Figure 6. Average weight-based doses of different induction anesthetics stratified by 
ASA class. 
 
Age-Related Dosing Stratified by ASA Class 
 When stratified by ASA class, the decreased dosing for older patients (>70 years 
old) continued to be significant for both midazolam and propofol within each ASA class 
stratification (p-values <0.01).  However, when stratified by ASA class, the age-based 
change in dosing for fentanyl was no longer significant (p=0.06 for ASA I/II, p=0.15 for 
ASA III/IV).  Table E 
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 Age 18-70 
[n=1628] 
Age > 70 
[n=241] 
P-value 
Midazolam (mcg/kg) 
    All Pts  
    ASA I/II 
    ASA III/IV 
 
0.018 
0.018 
0.018 
 
0.006 
0.008 
0.005 
 
<0.01 
<0.01 
<0.01 
Fentanyl (mcg/kg) 
    All Pts 
    ASA I/II 
    ASA III/IV 
 
1.30 
1.36 
1.27 
 
1.18 
1.17 
1.17 
 
<0.01 
0.06 
0.15 
Propofol (mg/kg) 
    All Pts 
    ASA I/II 
    ASA III/IV 
 
2.20 
2.34 
1.96 
 
1.70 
1.88 
1.65 
 
<0.01 
<0.01 
<0.01 
 
Table E. Dosing differences for IV induction anesthetics stratified by age and ASA class. 
ASA I/II (n=1076), ASA III/IV (n=793). p<0.05 considered significant. 
 
DISCUSSION 
Age-Related IV Induction Dosing 
 It is well known that elderly patients require 20-50% less for IV induction dosing 
than younger patients.  Propofol doses are often reduced by as much as 50% and the 
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initial doses of opioids should also be reduced by approximately 50% [44, 55].  The goal 
of our study was to investigate whether practitioners are generally following these 
recommendations by reducing IV induction dosing for the elderly.  However, even with 
our growing elderly population, there is very little data for the very elderly (>80 yr).  For 
example, there are 21 previously published datasets on propofol pharmacokinetics, and 
the pooled data contains 660 patients total, however only 6 of those patients are over the 
age of 80 [62].  
Based on our current cohort, there were significant reductions in the average IV 
induction dosing of propofol, midazolam and fentanyl with increasing age.  When 
comparing the 18-30 year old age group and the >80 year old age group, there was a 14% 
reduction in fentanyl dosing, a 34% reduction in propofol dosing, and a 93% reduction in 
midazolam dosing.  While these reductions in dosing were significant, the dose 
reductions for propofol were still in the upper limit of the recommended dosing range for 
the elderly.  The dose reductions for fentanyl were higher than the recommended dosing 
of 0.5-1 mcg/kg, and our study patients received on average more than 1 mcg/kg. 
 When stratified by ASA class, there was also a significant reduction in IV 
induction dosing of propofol and fentanyl with increasing ASA class.  Given the higher 
percentage of patients with higher ASA classes (III&IV) in older patients, this suggests 
that some component of the overall reduction in IV induction dosing could be in part due 
to overall severity of illness of the patient and pre-existing comorbidities present in older 
patients rather than age itself.   It has been shown that for patients undergoing ambulatory 
GI procedures that practitioners are more likely to adjust for ASA class than age [63].  To 
delineate the whether dosing reductions in this study were due to age or ASA class, the 
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study cohort was stratified by ASA class before age-based analysis was done.  The cohort 
was divided into ASA I/II (those who are healthy and with well-controlled disease) vs. 
ASA III/IV (those who have significant or poorly controlled disease) and then stratified 
by age.  Once controlled for ASA class, there continued to be a significant decrease in 
dosing for both midazolam and propofol with increasing age, suggesting that significant 
dose reductions seen in this study are in fact based on age in addition to those reductions 
seen in association with increasing ASA class.  However, there was no significant change 
in dosing of fentanyl based on age once stratified by ASA class.  This suggests that the 
reduction in dosing we noted in the unstratified age-based analysis was likely due to the 
increased proportion of ASA III/IV patients in the older age groups rather than actual 
changes in dosing based on age. 
 Once stratified by ASA class, those patients with higher ASA classifications over 
the age of 70 years still had doses of propofol that were in the upper limit of 
recommended dosing and doses of fentanyl that were above those recommended for the 
elderly.  This suggests that even those older patients with the most significant disease 
burden are receiving more IV induction anesthetic than necessary, especially when 
considering that these reductions in dosing were still associated with significant post-
induction blood pressure decreases. 
 
Post-induction hemodynamic changes 
We noticed greater post-induction hemodynamic changes in MAP with increasing 
age despite the decreased dosing in IV anesthetic.  We noted an age-dependent increase 
in the degree of post-induction hypotension.   Propofol and midazolam and known to 
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have hemodynamic effects that result in decreases in arterial blood pressure [44], and co-
administration of these two drugs has a synergistic effect [64].  Fentanyl, when used as 
the sole or primary induction agent, has been shown to result in hemodynamic stability 
throughout the perioperative period [55].  However studies have shown that when used in 
combination with propofol, opioids reduce the plasma propofol concentration required 
for loss of consciousness [65, 66].  Specifically, alfentanil has been shown to enhance the 
depressant effects of propofol on systolic blood pressure.  Hemodynamic stability 
therefore does not appear to be improved with combinations of propofol and alfentanil 
[66].  Studies combining midazolam, propofol and fentanyl show a synergistic effect of 
these drugs, which reflected by significant reductions in propofol dose requirement when 
adding midazolam pre-treatment to a standard propofol and fentanyl induction.  This 
synergistic effect appeared to be even more significant in the older age group (>60 yr).  
There was also a trend where the treatment group that did not receive midazolam tended 
to maintain systolic blood pressure more effectively than the treatment group that 
received all three drugs, although this effect was not statistically significant [67].  While 
this study did not determine each induction agent’s individual effect on blood pressure, 
the post-induction hemodynamic changes seen in this study are likely in part due to the 
synergistic action of the induction agents used, and this effect is likely more significant in 
the elderly. 
Older patients are known to show more hypotension and greater lability during 
anesthesia than young adults [6, 68, 69].  It is also well known that induction of 
anesthesia by bolus administration of propofol can produce significant hypotension [70-
72].  There is evidence that hypotension and hypertension during general anesthesia are 
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independently associated with adverse outcomes in patients having both non-cardiac and 
cardiac surgery [59, 61, 73, 74].  While the consequences of post-induction hypotension 
are not yet entirely known, a study by Reich et al noted in a retrospective review that 9% 
of their patients experienced severe hypotension 0 to 10 minutes post-induction of 
general anesthesia.  The patients with post-induction hypotension were more likely to 
experience prolonged postoperative stays and/or death than those patients without post-
induction hypotension.  The proportion of those adverse events in patients with 
hypotension at any time during the first 10 minutes following induction was 13.3%, 
versus 8.6% in patients without hypotension, during this post-induction period [61].  A 
prospective cohort study by Monk et al also showed that 1-year mortality risk was 
increased with longer duration of intraoperative hypotension.   There was a 0.36 % 
increase in mortality risk per minute when the mean arterial pressure was below 80 mm 
Hg in patients with intraoperative hypotension [59].  More recently, Walsh et al found 
that patients with intraoperative hypotension where the mean arterial pressure fell below 
55 mmHg had an increased risk for both acute kidney injury and myocardial injury.  Even 
short durations (1 to 5 minutes) of hypotension were associated with an increased risk for 
these adverse outcomes, however the risk increased with increased duration of 
intraoperative hypotension [74].   
The elderly population is especially at risk for post-induction hypotension given 
the pathophysiological changes associated with aging.  There is decreased baroreceptor 
sensitivity with increasing age, which impairs the ability to buffer short-term changes in 
blood pressure.  Decreased responsiveness to β-adrenoreceptors and the renin-
angiotensin-aldosterone system stimulation also increases the risk for hypotension in 
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older patients [10].  Given the increased risk of both morbidity and mortality associated 
with even short durations of post-induction hypotension, careful management of IV 
induction dosing and hemodynamics in the elderly could improve the postoperative 
outcomes for these patients. 
While the average mean arterial pressures reflected an increase in the degree of 
post-induction hypotension in older patients, there were large standard deviations 
associated with these pressures. This reflects the degree of pathophysiological variability 
and pharmacological variability in regards to individual response to varying IV induction 
agents.  This could in part be due to the tremendous variability in physical status of 
elderly patients [54], it could also be due to the variability across different anesthesia 
providers.   
Data on rate of drug administration are missing in this retrospective review.  The 
assumption in this study is that induction doses are given as bolus injections rather than 
steady infusions.  Studies have shown that while bolus administration of drugs such as 
propofol commonly produce significant hypotension following induction [71, 72], 
induction with a slow infusion (0.75 mg/kg/min) with propofol at total doses of 
approximately 1.6 mg/kg does not significantly decrease blood pressure in the elderly 
(defined as 65 to 85 yrs by Chan et al), and it does not require significantly longer to 
achieve loss of consciousness [70].  It is likely that this reduction in the infusion rate 
attenuates the peak drug concentration and thus has a lesser effect on the hemodynamics. 
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Study Limitations 
A major limitation to this study is the retrospective nature of the review.  We were 
constrained to the data that were collected by the clinicians, though automated, at the 
time.  Therefore our dosing data were entirely reliant on the documentation in the 
electronic medical record.  Knowing that the induction of anesthesia is often a busy time 
for the anesthesia staff, it is quite possible that the documentation is done after the fact.  
This could result in modest variation between actual time of induction and the 
documented time of induction.  We also do not have data on fluid therapy, positional 
changes, mildly stimulating procedures (such as urinary bladder catheterization) or any 
other factors that could have influenced blood pressure.   
In the current study, we did not exclude patients if the post-induction blood 
pressure measurement was taken after intubation.  Tachycardia and hypertension are 
well-documented complications associated with laryngoscopy and tracheal intubation 
[75, 76], and typical pressor response can include a 40-50% increase in blood pressure, a 
20% increase in heart rate and an elevation in both plasma epinephrine and 
norepinephrine [77].  It is very likely that for a proportion of the patients in this study 
cohort with noted post-induction increases in blood pressure, this increase in blood 
pressure was due to the pressor response associated with tracheal intubation.  While 
elderly patients (65-80 yr) have been shown to have a decreased chronotropic response to 
intubation, there have been no documented age-related differences in the effect of 
laryngoscopy and tracheal intubation on mean arterial pressure [78, 79].  Therefore, while 
the pressor response associated with tracheal intubation likely attenuated the magnitude 
of post-induction hypotension noted in the overall study, it is not likely to have 
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significantly affected the age-related differences in post-induction blood pressure that 
were seen in this study. 
Like the vast majority of age-related studies, the current study is cross-sectional 
and the age-related differences inferred here are based on comparisons of mean values 
between the various age groups.  This assumes that mean differences observed between 
age groups reflect the change that occurs in an individual with the passage of time, which 
may not always be valid.  Cross-sectional studies can often confound time-related factors 
of age and birth cohort effects [39]  For example, generational differences in regards to 
things such as environmental exposures and access to healthcare could be confounding 
the age-related effects seen in this study.  There may also be certain selective mortality 
biases in a cross-sectional study because the individuals in the oldest cohort have 
survived to reach old age.  Ideally, longitudinal studies provide the best data on the 
effects of aging, however it would be difficult to obtain longitudinal data on the effects of 
IV induction anesthetics as that would require a patient cohort that would require regular 
invasive procedures that require general anesthesia.   
The data collection for this study was done at one institution, and therefore the 
overall generalizability of the study is somewhat limited.  Further studies utilizing large 
databases or multi-center studies would be beneficial to confirm the results obtained at 
this institution, and it would improve the generalizability of the study results.  However, 
previous studies at other institutions have given similar results, which is reassuring that 
the results of this study are not institution-specific [80, 81].  
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Recommendations and Future Directions 
 This study is one of the many suggesting that older patients are routinely given 
more IV anesthetic than is recommended for their age [63, 80-82].  While dose reductions 
noted in this study are within the recommended range for older patients, the fact that 
these doses were still associated with significant drop in mean arterial pressure suggests 
that further dose reductions may be required for older patients.  With the increasing 
population of patients over the age of 65 years, it may be necessary to look at age as a 
continuous variable when considering anesthetic drug dosing in older patients rather than 
treating “adult” versus “elderly” patients.  This study noted that post-induction decline in 
mean arterial pressure were greater with increasing age, suggesting that our current drug 
dosing recommendations for the elderly may not be sufficient.  Very little is known about 
the pharmacodynamics differences in those aged >85 years old [39], and this is one of the 
fastest growing populations in the United States [3].  There are data showing that 
adequate levels of anesthesia can be provided with doses of propofol as low as 0.82 
mg/kg for both bolus and infusion dosing [83].   
 Further study in this very elderly population (>85 yr) would be helpful to 
delineate the PK/PD differences in this population beyond what has been studied for 
those patients over the age of 65.  Titrated dosing with commonly used IV induction 
agents in addition to blinded EEG monitoring will help to determine whether the PK/PD 
changes in the very elderly are different in comparison to the data previously discussed 
regarding patients over the age of 65.  While this study did show a progressively 
increasing hemodynamic response to IV induction agents with increasing age, it has been 
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well established that hemodynamic variables are not predictive of hypnotic depth [59].  
Therefore, adequate depth of anesthesia must be established with either intraoperative 
EEG or BIS monitoring before the dosing of IV anesthetics can be lowered when trying 
to maintain hemodynamic stability in these patients. 
Until there are more detailed studies looking at the pharmacokinetic and 
pharmacodynamics differences in adults >85 years old, perhaps it would be beneficial for 
there to be progressive dose reductions with increasing age for older patients to prevent 
perioperative complications such as post-induction hypotension and improve 
hemodynamic stability for older patients in the operating room.   
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